<strong class="h5 indication-title text-warning">Indications</strong>

Non-Hodgkin’s Lymphoma (NHL)

RIABNI^® (rituximab-arrx) is indicated for the treatment of adult patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.
Chronic Lymphocytic Leukemia (CLL)

RIABNI^®, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.
Rheumatoid Arthritis (RA)
- RIABNI^®, in combination with methotrexate, is indicated for the treatment of adult patients with moderately- to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
RIABNI^®, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).

BEHIND RIABNI^® ANSWERING THE GROWING NEED FOR BIOSIMILARS

Amgen is a leader in biologics with a growing portfolio in biosimilars.

HERITAGE

THE HEALTHCARE COMMUNITY HAS BEEN ABLE TO TRUST US FOR DECADES

AT AMGEN, WE’RE COMMITTED TO EVERY PATIENT, EVERY TIME.
Expertise
REAL-WORLD EXPERIENCE AND EXPERTISE PAVED THE WAY FOR OUR LEADERSHIP IN BIOSIMILARS
- *Available biosimilars across all global markets.
Commitment

WE ARE A LONG-STANDING BIOTECHNOLOGY LEADER COMMITTED TO DEVELOPING THE BIOSIMILAR MARKETPLACE

Invested in the development of biosimilars and novel therapeutics

OUR BIOSIMILAR PIPELINE IS TARGETED TO ADDRESS THE GREATEST TREATMENT NEEDS WITHOUT COMPROMISING HIGH-LEVEL CUSTOMER SERVICE^1-5
Support

WE ARE COMMITTED TO PROVIDING SOLUTION-ORIENTED RESOURCES THAT CAN HELP PROVIDE POSITIVE BIOSIMILAR EXPERIENCES

Amgen stands with our local Los Angeles community. Click here to learn what we are doing to support and contact us if the fires have impacted your access to Amgen medication.

BEHIND RIABNI® ANSWERING THE GROWING NEED FOR BIOSIMILARS

THE HEALTHCARE COMMUNITY HAS BEEN ABLE TO TRUST US FOR DECADES

REAL-WORLD EXPERIENCE AND EXPERTISE PAVED THE WAY FOR OUR LEADERSHIP IN BIOSIMILARS

WE ARE A LONG-STANDING BIOTECHNOLOGY LEADER COMMITTED TO DEVELOPING THE BIOSIMILAR MARKETPLACE

WE ARE COMMITTED TO PROVIDING SOLUTION-ORIENTED RESOURCES THAT CAN HELP PROVIDE POSITIVE BIOSIMILAR EXPERIENCES

IMPORTANT SAFETY INFORMATION AND INDICATIONS

BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Warnings and Precautions

Tumor Lysis Syndrome

Infections

Cardiovascular Adverse Reactions

Renal Toxicity

Bowel Obstruction and Perforation

Immunization

Embryo-Fetal Toxicity

Concomitant Use with Other Biologic Agents and DMARDs other than Methotrexate in RA, GPA, and MPA

Use in RA Patients Who Have Not Had Prior Inadequate Response to Tumor Necrosis Factor (TNF) Antagonists

Most Common Adverse Reactions

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI® infusion and advise patients to read guide.

INDICATIONS

IMPORTANT SAFETY INFORMATION AND INDICATIONS

BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Warnings and Precautions

Infusion-Related reactions (IRR)

Severe Mucocutaneous Reactions

Hepatitis B Virus Reactivation

Progressive Multifocal Leukoencephalopathy (PML)

Tumor Lysis Syndrome

Infections

Cardiovascular Adverse Reactions

Renal Toxicity

Bowel Obstruction and Perforation

Immunization

Embryo-Fetal Toxicity

Additional Important Safety Information

Adverse Reactions

Pregnancy and Nursing Mothers

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI® infusion and advise patients to read guide.

Indications

Non-Hodgkin’s Lymphoma (NHL)

Chronic Lymphocytic Leukemia (CLL)

Connect with an Amgen Oncology representative

Privacy Statement

BEHIND RIABNI^® ANSWERING THE GROWING NEED FOR BIOSIMILARS

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI^® infusion and advise patients to read guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI^® infusion and advise patients to read guide.